Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial

AIMS: We previously reported that in the EMPA-REG OUTCOME(®) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular events, cardiovascular and all-cause death, and hospitalization for heart failure in patients with type 2 diabetes and high cardiovascu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Heart J
Autors principals: Fitchett, David, Zinman, Bernard, Wanner, Christoph, Lachin, John M., Hantel, Stefan, Salsali, Afshin, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Inzucchi, Silvio E.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Aha Fasttrack
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872285/
https://ncbi.nlm.nih.gov/pubmed/26819227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehv728
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars